Oncology Drug Costs Can Be ‘Financial Toxicity,’ ASCO Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Memorial Sloan Kettering’s Saltz challenges oncology drug prices and urges a broader focus on value in a high-profile address to the ASCO annual meeting.